{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:17:25Z","timestamp":1778073445487,"version":"3.51.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.schres.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T18:45:30Z","timestamp":1582829130000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Perspective on medication decisions following remission from first-episode psychosis"],"prefix":"10.1016","volume":"225","author":[{"given":"Christy L.M.","family":"Hui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertha S.T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin H.M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.N.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y.H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.02.007_bb0010","first-page":"50","article-title":"Clinical practice guidelines. Treatment of schizophrenia","author":"Addington","year":"2005","journal-title":"Can. J. Psychiatr."},{"issue":"2\u20103","key":"10.1016\/j.schres.2020.02.007_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.schres.2010.10.013","article-title":"Predictors of recovery from psychosis: analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years","volume":"125","author":"Albert","year":"2011","journal-title":"Schizophrenia research"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.02.007_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-9964(00)00187-0","article-title":"Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study","volume":"52","author":"Altamura","year":"2001","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"S33","key":"10.1016\/j.schres.2020.02.007_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000297663","article-title":"Early intervention in psychosis: the critical period hypothesis","volume":"172","author":"Birchwood","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004714-199102000-00004","article-title":"The concept of the neuroleptic threshold: an update","volume":"11","author":"Bitter","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.02.007_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0920-9964(00)00144-4","article-title":"Duration of untreated psychosis predicts treatment outcome in an early psychosis program","volume":"47","author":"Black","year":"2001","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2020.02.007_bb0050","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.4088\/JCP.11m07246","article-title":"Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database","volume":"73","author":"Bushe","year":"2012","journal-title":"The Journal of clinical psychiatry"},{"issue":"S43","key":"10.1016\/j.schres.2020.02.007_bb0055","doi-asserted-by":"crossref","first-page":"s66","DOI":"10.1192\/bjp.181.43.s66","article-title":"Brain morphology in antipsychotic-naive schizophrenia: a study of multiple brain structures","volume":"181","author":"Cahn","year":"2002","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.schres.2020.02.007_bb0060","series-title":"Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder","author":"Catalan Agency for Health Technology Assessment and Research","year":"2009"},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamapsychiatry.2018.0185","article-title":"Association of an early intervention service for psychosis with suicide rate among patients with first-episode schizophrenia-spectrum disorders","volume":"75","author":"Chan","year":"2018","journal-title":"JAMA psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0253-7176.135383","article-title":"Attitudes toward medication and reasons for non-compliance in patients with schizophrenia","volume":"36","author":"Chandra","year":"2014","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.schres.2020.02.007_bb0075","doi-asserted-by":"crossref","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00427637","article-title":"Stimulus efficacy, chlorpromazine, and schizophrenia","volume":"69","author":"Clody","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2020.02.007_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"Br Psychiat"},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12035-013-8534-3","article-title":"Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches","volume":"49","author":"de Bartolomeis","year":"2014","journal-title":"Mol. Neurobiol."},{"issue":"S279","key":"10.1016\/j.schres.2020.02.007_bb0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1980.tb07084.x","article-title":"Do schizophrenics well adapted in the community need neuroleptics?: a depot neuroleptic withdrawal study","volume":"61","author":"Dencker","year":"1980","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia","volume":"7","author":"Falkai","year":"2006","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/schbul\/10.3.412","article-title":"Developing and maintaining adherence to long-term drug-taking regimens","volume":"10","author":"Falloon","year":"1984","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2020.02.007_bb0135","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2020.02.007_bb0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0447.1999.tb05990.x","article-title":"Subjective experience and mental side-effects of antipsychotic treatment","volume":"99","author":"Gerlach","year":"1999","journal-title":"Acta Psychiatr. Scand."},{"issue":"8","key":"10.1016\/j.schres.2020.02.007_bb0150","first-page":"40","article-title":"Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients","volume":"19","author":"Gibson","year":"2010","journal-title":"Managed care (Langhorne, Pa.)"},{"issue":"11","key":"10.1016\/j.schres.2020.02.007_bb0155","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pscychresns.2006.10.002","article-title":"Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug","volume":"154","author":"Glenthoj","year":"2007","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"9","key":"10.1016\/j.schres.2020.02.007_bb0165","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14740338.2011.560112","article-title":"Risk of osteoporosis and fracture incidence in patients on antipsychotic medication","volume":"10","author":"Graham","year":"2011","journal-title":"Expert opinion on drug safety"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.02.007_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0920-9964(95)00108-5","article-title":"Relapse in schizophrenia: is there a relationship to substance abuse?","volume":"20","author":"Gupta","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.02.007_bb0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient related outcome measures"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopsych.2014.07.011","article-title":"Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity","volume":"77","author":"Hall","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb9015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1017\/S003329170200675X","article-title":"Does treatment delay in first-episode psychosis really matter?","volume":"33","author":"Harrigan","year":"2003","journal-title":"Psychological Medicine"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2020.02.007_bb0200","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1017\/S0033291712000220","article-title":"Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study","volume":"42","author":"Harrow","year":"2012","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.schres.2020.02.007_bb0210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-3956(97)00013-7","article-title":"The limited effects of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment","volume":"32","author":"Hogarty","year":"1998","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0215","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0220","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.schres.2020.02.007_bb0225","first-page":"1","article-title":"A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first-and multi-episode schizophrenia","author":"Hui","year":"2019","journal-title":"International Review of Psychiatry"},{"key":"10.1016\/j.schres.2020.02.007_bb0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijbiomac.2018.01.121","article-title":"Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers","volume":"110","author":"Jawahar","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0447.1976.tb00015.x","article-title":"The duration of maintenance therapy in chronic schizophrenia","volume":"53","author":"Johnson","year":"1976","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","article-title":"Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia","volume":"39","author":"Kane","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0250","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0255","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am. J. Psychiatr."},{"issue":"10","key":"10.1016\/j.schres.2020.02.007_bb0265","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"The Journal of clinical psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0270","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.socscimed.2005.08.016","article-title":"Stigmatizing experience and structural discrimination associated with the treatment of schizophrenia in Hong Kong","volume":"62","author":"Lee","year":"2006","journal-title":"Soc. Sci. Med."},{"issue":"2 Suppl","key":"10.1016\/j.schres.2020.02.007_bb0275","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb9010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb9000","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Molecular Psychiatry"},{"issue":"9657","key":"10.1016\/j.schres.2020.02.007_bb9005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1461145710001380","article-title":"Evidence-based pharmacotherapy of schizophrenia","volume":"14","author":"Leucht","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9831","key":"10.1016\/j.schres.2020.02.007_bb0285","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0295","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.neuro.25.112701.142754","article-title":"Schizophrenia as a disorder of neurodevelopment","volume":"25","author":"Lewis","year":"2002","journal-title":"Annu. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","article-title":"Catching up on schizophrenia: natural history and neurobiology","volume":"28","author":"Lewis","year":"2000","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.schres.2020.02.007_bb0305","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.02.007_bb9030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.schres.2007.07.022","article-title":"Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: A meta-analysis","volume":"96","author":"Lincoln","year":"2007","journal-title":"Schizophrenia Research"},{"issue":"8","key":"10.1016\/j.schres.2020.02.007_bb0310","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0320","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00176470","article-title":"The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness","volume":"92","author":"Miller","year":"1987","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00048678909062141","article-title":"Hyperactivity of associations in psychosis","volume":"23","author":"Miller","year":"1989","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0330","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.02.007_bb0335","first-page":"25","article-title":"Developing novel antipsychotic drugs: strategies and goals","volume":"2","author":"Miyamoto","year":"2000","journal-title":"Curr Opin CPNS Invest Drugs"},{"key":"10.1016\/j.schres.2020.02.007_bb0340","series-title":"Neuropsychopharmacology: The Fifth Generation of Progress","first-page":"775","article-title":"Therapeutics of schizophrenia","author":"Miyamoto","year":"2002"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0345","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eurpsy.2011.06.009","article-title":"Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication\u2013a 10-year follow-up of the Northern Finland 1966 Birth Cohort study","volume":"28","author":"Moilanen","year":"2013","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","article-title":"Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse","volume":"114","author":"Moncrieff","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2020.02.007_bb0355","doi-asserted-by":"crossref","first-page":"b1963","DOI":"10.1136\/bmj.b1963","article-title":"How do psychiatric drugs work?","volume":"338","author":"Moncrieff","year":"2009","journal-title":"Br. Med. J."},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0360","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1017\/S0033291718003811","article-title":"A critical analysis of recent data on the long-term outcome of antipsychotic treatment","volume":"49","author":"Moncrieff","year":"2019","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0365","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Physician"},{"issue":"7 Suppl","key":"10.1016\/j.schres.2020.02.007_bb0370","first-page":"S170","article-title":"Metabolic syndrome and mental illness","volume":"13","author":"Newcomer","year":"2007","journal-title":"Am. J. Manag. Care"},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0385","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Archives of general psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.02.007_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/j.1440-1614.2005.01516.x","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders","year":"2005","journal-title":"Aust. N.Z.J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2850.2004.00641.x","article-title":"Did anything change? Caregivers and schizophrenia after medication changes","volume":"11","author":"Rudge","year":"2004","journal-title":"J. Psychiatr. Ment. Health Nurs."},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0400","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/09540260701278911","article-title":"Is antipsychotic medication stigmatizing for people with mental illness?","volume":"19","author":"Sajatovic","year":"2007","journal-title":"International Review of Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2020.02.007_bb0405","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0410","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb9020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.bp.114.158931","article-title":"Shared treatment decision-making and empowerment related outcomes in psychosis: Systematic review and meta-analysis","volume":"209","author":"Stovell","year":"2016","journal-title":"The British Journal of Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.02.007_bb0415","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-9964(95)00068-2","article-title":"Substance use: a powerful predictor of relapse in schizophrenia","volume":"20","author":"Swofford","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.02.007_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000284","article-title":"Chlorpromazine versus placebo for schizophrenia","volume":"2","author":"Thornley","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.schres.2020.02.007_bb0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1600-0447.2000.102003211.x","article-title":"The relationship between insight and medication adherence in severely mentally ill clients treated in the community","volume":"102","author":"Trauer","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0430","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jcop.10055","article-title":"Stigmatizing attitudes towards individuals with mental illness in Hong Kong: implications for their recovery","volume":"31","author":"Tsang","year":"2003","journal-title":"Journal of Community Psychology"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11065-014-9248-7","article-title":"Brain networks in schizophrenia","volume":"24","author":"van den Heuvel","year":"2014","journal-title":"Neuropsychol. Rev."},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0440","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ajp.149.4.500","article-title":"Haloperidol plasma levels and clinical response: a therapeutic window relationship","volume":"149","author":"Van Putten","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.02.007_bb0445","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0447.2012.01883.x","article-title":"Symptomatic and functional remission in patients with first-episode psychosis","volume":"126","author":"Verma","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0450","first-page":"521","article-title":"Ministry of Health Clinical Practice Guidelines: Schizophrenia","volume":"52","author":"Verma","year":"2017","journal-title":"Singapore Medical Journal"},{"issue":"2","key":"10.1016\/j.schres.2020.02.007_bb0455","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.schbul.a006943","article-title":"Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders","volume":"28","author":"Weiss","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"7527","key":"10.1016\/j.schres.2020.02.007_bb0460","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nature13716","article-title":"Synaptic dysregulation in a human iPS cell model of mental disorders","volume":"515","author":"Wen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.schres.2020.02.007_bb0465","series-title":"Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions","author":"WHO","year":"2004"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb9025","first-page":"33","article-title":"Issues for further refinement of family interventions in schizophrenia","volume":"2","author":"Wiedemann","year":"2003","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0470","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2020.02.007_bb0475","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","article-title":"A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients","volume":"64","author":"Wistedt","year":"1981","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2020.02.007_bb0480","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1176\/ajp.146.7.905","article-title":"Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia","volume":"146","author":"Wolkin","year":"1989","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.02.007_bb0485","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2020.02.007_bb0490","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2020.02.007_bb0500","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"The Lancet Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.02.007_bb0505","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2020.02.007_bb0510","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/appi.ajp.159.10.1653","article-title":"Interventions to improve medication adherence in schizophrenia","volume":"159","author":"Zygmunt","year":"2002","journal-title":"Am. J. Psychiatr."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420300839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420300839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:37:20Z","timestamp":1760297840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420300839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":96,"alternative-id":["S0920996420300839"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.02.007","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspective on medication decisions following remission from first-episode psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}